Evidence map›Paper›PMID 42650005›Full record

ArticleCancers2026

Clinicopathological Predictors of Recurrence in Resected Stage IIB-IIIB Melanoma: The Prognostic Impact of Stage IIC in a Real-World Cohort.

Icíar De La Fuente Domínguez, Pedro Sánchez Mauriño, Luis Pérez Bartivas, María Sánchez-Lopera, Rafael Sánchez Sánchez, Enrique Aranda Aguilar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Icíar De La Fuente DomínguezUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.ORCID 0000-0003-2573-8039
Pedro Sánchez MauriñoUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.
Luis Pérez BartivasUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.
María Sánchez-LoperaUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.
Rafael Sánchez SánchezUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.
Enrique Aranda AguilarUniversity of Córdoba, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofía University Hospital, 14004 Córdoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvant immunotherapyBRAFmelanomaprognosisrecurrencesentinel lymph nodestage IIC

Identifiers

PMID42650005
PMCPMC13510437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.